Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: In vitro and in vivo evaluations

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 4029-4041

  Alai, Milind ^a   Lin, Wen Jen ^a,b  

^a Grad Inst of Pharmacognosy Science   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Eudragit RS100; Lansoprazole; Nanoparticles; PLGA

Indexed keywords

EUDRAGIT; LANSOPRAZOLE; NANOPARTICLE; ANTIULCER AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; RAT; STOMACH ULCER; SURFACE CHARGE; TIME TO MAXIMUM PLASMA CONCENTRATION; TIMED DRUG RELEASE; ANIMAL; CACO-2 CELL LINE; CHEMISTRY; HUMAN; ORAL DRUG ADMINISTRATION; WISTAR RAT;

RATTUS NORVEGICUS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ULCER AGENTS; CACO-2 CELLS; HUMANS; LANSOPRAZOLE; NANOPARTICLES; RATS; RATS, WISTAR; STOMACH ULCER;

EID: 84933525070     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S82366     Document Type: Article

References (35)

1. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61:1801–1833.
2. Zhang D, Yang M, Liu M, et al. Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. Xenobiotica. 2012;42:1156–1162.
3. Baldi F. Lansoprazole oro-dispersible tablet – pharmacokinetics and therapeutic use in acid-related disorders. Drugs. 2005;65(10): 1419–1426.
4. Stedman CA, Barclay ML. Review article: comparison of the pharma-cokinetics, acid suppression and effcacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:963–978.
5. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31:3657–3666.
6. Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005;22:20–24.
7. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther. 2007;25:197–205.
8. Wu ZM, Zhou LY, Guo XD, et al. HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharm. 2012; 425:1–8.
9. Adibkia K, Javadzadeh Y, Dastmalchi S, Mohammadi G, Niri FK, Alaei-Beirami M. Naproxen-Eudragit RS100 nanoparticles: preparation and physicochemical characterization. Colloids Surf B Biointerfaces. 2011; 83:155–159.
10. Devarajan PV, Sonavane GS. Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers. Drug Dev Ind Pharm. 2007;33:101–111.
11. Dai J, Nagai T, Wang X, Zhang T, Meng M, Zhang Q. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm. 2004;280:229–240.
12. Wang H, Jia Y, Hu W, Jiang H, Zhang J, Zhang L. Effect of preparation conditions on the size and encapsulation properties of mPEG-PLGA nanoparticles simultaneously loaded with vincristine sulfate and cur-cumin. Pharm Dev Technol. 2013;18:694–700.
13. Cetin M, Atila A, Sahi S, Vural I. Preparation and characterization of metformin hydrochloride loaded-Eudragit®RSPO and Eudragit®RSPO/ PLGA nanoparticles. Pharm Dev Technol. 2013;18:570–576.
14. Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the infamed intestinal mucosa. J Control Release. 2012; 161:235–246.
15. Hassani S, Pellequer Y, Lamprecht A. Selective adhesion of nanoparticles to infamed tissue in gastric ulcers. Pharm Res. 2009;26:1149–1154.
16. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983; 15:25–35.
17. Algieri C, Drioli E, Donato L. Development of mixed matrix membranes for controlled release of ibuprofen. J Appl Polym Sci. 2013; 128:754–760.
18. Alai MS, Lin WJ. A novel nanoparticulate system for sustained delivery of acid-labile lansoprazole. Colloids Surf B Biointerfaces. 2013; 111:453–459.
19. Raffn RP, Colome LM, Pohlmann AR, Guterres SS. Preparation, characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded microparticles. Eur J Pharm Biopharm. 2006;63:198–204.
20. Ito Y, Arai H, Uchino K, Iwasaki K, Shibata N, Takada K. Effect of adsorbents on the absorption of lansoprazole with surfactant. Int J Pharm. 2005; 289:69–77.
21. Alai MS, Lin WJ. Novel lansoprazole-loaded nanoparticles for the treatment of gastric acid secretion-related ulcers: in vitro and in vivo pharma-cokinetic pharmacodynamic evaluation. AAPS J. 2014;16:361–372.
22. Johnson CE, Cober MP, Ludwig JL. Stability of partial doses of omeprazole-sodium bicarbonate oral suspension. Ann Pharmacother. 2007;41: 1954–1961.
23. Alai MS, Lin WJ. A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal refux disease: preparation, pharmacoki-netic and pharmacodynamic evaluation. J Microencapsul. 2013;30: 519–529.
24. Sun WZ, Lin WJ, Alai MS. Preparation of microparticles for acid-labile lansoprazole by solvent evaporation method combined with a spray drying process. J Food Drug Anal. 2012;20:438–445.
25. Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine. 2010; 6:318–323.
26. Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/ prednisolone bitherapy. Mol Pharm. 2010;7:576–585.
27. Garcia X, Escribano E, Domenech J, Queralt J, Freixes J. In vitro characterization and in vivo analgesic and anti-allodynic activity of PLGA-bupivacaine nanoparticles. J Nanopart Res. 2011;13: 2213–2223.
28. Sun B, Ranganathan B, Feng SS. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials. 2008;29:475–486.
29. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713–2722.
30. Dong Y, Feng SS. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005; 26:6068–6076.
31. Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Effect of fuoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. Clin Drug Investig. 2011;31:727–733.
32. Song M, Gao X, Hang TJ, Wen AD. Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: a single-dose, open-label study in healthy Chinese male subjects. Curr Ther Res Clin Exp. 2009;70:228–239.
33. Stefanič M, Locatelli I, Vrečer F, Sever T, Mrhar A, Bogataj M. The infu-ence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: an in vitro/in vivo correlation. Eur J Pharm Biopharm. 2012;82:376–382.
34. Capurso G, Marignani M, Attilia F, et al. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. Dig Liver Dis. 2011;43: 380–385.
35. Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci. 2005;50:S24–S33.